MedTrace Logo

Pharmacokinetic and Efficacy of SQV/r 1500/100 Plus Tenofovir/Emtricitabine 300/200 mg

NCT00476983 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2015-03-30

No results posted yet for this study

Summary

Pharmacokinetic and long term efficacy of TDF SQV film coated tablet 1500/100mg once daily plus TDF/FTC300/200mg once daily.

Conditions

  • Saquinavir/Ritonavir BID or Lopinavir/Ritonavir BID

Interventions

DRUG

saquinavir/ritonavir plus truvada

SQV/r 1500/100 mg OD + Truvada OD for 2 years

Sponsors & Collaborators

  • The HIV Netherlands Australia Thailand Research Collaboration

    lead OTHER

Principal Investigators

  • Kiat Ruxrungtham, MD · The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00476983 on ClinicalTrials.gov